Login to Your Account



Eleven comes back, takes Viventia via stock merger

By Randy Osborne
Staff Writer

Wednesday, September 21, 2016

CEO Stephen Hurly told BioWorld Today that Viventia Bio Inc.'s bid to lift ADCs "to the next level" in oncology powered a merger deal with Eleven Biotherapeutics Inc., a peer in protein engineering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription